MIJ is pleased to announce that we have invested in ILC Therapeutics Ltd., a British start-up company in the life science sector. ILC Therapeutics is developing a new interferon product for use as a therapeutic drug against SARS-CoV-2. Moreover, this new drug candidate also shows potential for broad application as a therapeutic drug for other viral diseases, immune diseases, and cancers, and is expected to fulfill unmet needs for the treatment of intractable diseases.